Ask AI
Integrating BTK Inhibitors in CLL

CME

Conference to Clinic—Advancing Integration of BTK Inhibitors in CLL/SLL Treatment: Expert Insights on Evolving Approaches to Optimize Care

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 11, 2025

Expiration: May 10, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 1: 63-Yr-Old Man With Newly Diagnosed CLL



  • A 63-yr-old man was diagnosed with CLL

    • del (17p)/TP53 wild type

    • IGHV mutation



  • The patient has a past medical history of hypertension and diabetes

  • The patient needs to initiate therapy because of symptoms and cytopenias

  • He desires a fixed-duration, all-oral regimen because of his career as a truck driver

Which of the following would you recommend as the best first-line therapy for this patient?

2.

Patient Case: An 86-Yr-Old Man With Relapsed CLL



  • An 86-yr-old man was diagnosed with CLL in 2013 and has experienced multiple relapses

    • Initially diagnosed as Rai stage 1, IGHV unmutated, FISH reveals trisomy 12



  • He has received bendamustine + rituximab in 2014, followed by venetoclax + rituximab from 2016 to 2018, and acalabrutinib in 2019

  • He has remained on acalabrutinib but recently developed worsening lymphocytosis and rapidly enlarging lymph nodes, consistent with progressing CLL but without clinical or laboratory signs of Richter transformation

  • NGS revealed acquired BTK C481S mutation

  • He states that he would prefer another oral therapy in his next line of treatment

Which of the following would you recommend as the best next-line therapy for this 86-yr-old patient?

3.

How confident are you in your ability to plan individualized treatment approaches for relapsed/refractory CLL?

4.

How confident are you in your ability to educate your patients receiving BTKi therapy about associated adverse events?